Evidence map›Paper›PMID 34012511›Full record

ArticleOncotarget2021

Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity.

Sarah Kemski, Vivien Molitor, Michael Steffens, Tim J Nümm, Nadine Herrmann, Thorsten Hornung, Thomas Bieber, Christian Schumann, Volker Kächele, Thomas Seufferlein and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Sarah KemskiResearch Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
Vivien MolitorResearch Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
Michael SteffensResearch Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
Tim J NümmDepartment of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education (CK-CARE), University Hospital-Bonn, Bonn, Germany.
Nadine HerrmannDepartment of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education (CK-CARE), University Hospital-Bonn, Bonn, Germany.
Thorsten HornungDepartment of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education (CK-CARE), University Hospital-Bonn, Bonn, Germany.
Thomas BieberDepartment of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education (CK-CARE), University Hospital-Bonn, Bonn, Germany.
Christian SchumannDepartment of Pulmonology, Thorax Oncology, Sleep and Respiration Medicine, Hospital Group Allgäu, Kempten, Germany.
Volker KächeleMedical Centre for Haematology and Oncology, Ulm, Germany.
Thomas SeufferleinDepartment of Internal Medicine I, University of Ulm, Ulm, Germany.
Volker HeinemannDepartment of Internal Medicine III, Ludwig-Maximilians-University of Munich, Munich, Germany.
Catharina SchollResearch Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
Julia Carolin StinglInstitute of Clinical Pharmacology, University Hospital of the RWTH Aachen, Aachen, Germany.
Federal Institute for Drugs and Medical Devices · DEUniversity Hospital Bonn · DELudwig-Maximilians-Universität München · DERWTH Aachen University · DEUniversität Ulm · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEpidermal growth factor receptor inhibitors (EGFRI) are used as targeted cancer therapy. On average 70% of patients treated with EGFRIs suffer from skin toxicity. Studies showed a correlation between overall survival and the appearance of a skin rash, which is used as a biomarker for therapy efficacy. Micro RNAs (miRNA) as tumor or resistance biomarkers for cancer therapy are also highly investigated. In our study, we searched for associations of miRNA expression profiles in serum, with the severity of skin rash, in order to identify tentative therapy predictive biomarkers. MATERIALS AND

methodsFive candidate miRNAs were selected, based on an earlier

resultsIn our cohort of patients treated with EGFR inhibiting monoclonal antibodies, miR-21 and miR-520e serum concentrations were negatively correlated with severity of skin rash (

conclusionsThis suggests that miR-21, miR-31 and miR-520e expression might be a treatment dependent marker for EGFRI induced skin rash.

Indexed as

cancerEGFREGFRImiRNAskin toxicity

Identifiers

PMID34012511
PMCPMC8121613
OpenAlexW3157628665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.